SE0602516L - Behandling och diagnos av insulinresistenta tillstånd - Google Patents

Behandling och diagnos av insulinresistenta tillstånd

Info

Publication number
SE0602516L
SE0602516L SE0602516A SE0602516A SE0602516L SE 0602516 L SE0602516 L SE 0602516L SE 0602516 A SE0602516 A SE 0602516A SE 0602516 A SE0602516 A SE 0602516A SE 0602516 L SE0602516 L SE 0602516L
Authority
SE
Sweden
Prior art keywords
insulin
diagnosis
treatment
resistant conditions
resistant
Prior art date
Application number
SE0602516A
Other languages
English (en)
Inventor
Venita I Dealmeida
Timothy A Stewart
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SE0602516L publication Critical patent/SE0602516L/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
SE0602516A 2001-10-15 2006-11-27 Behandling och diagnos av insulinresistenta tillstånd SE0602516L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32994701P 2001-10-15 2001-10-15
PCT/US2002/032874 WO2003032810A2 (en) 2001-10-15 2002-10-15 Treatment and diagnosis of insulin resistant states

Publications (1)

Publication Number Publication Date
SE0602516L true SE0602516L (sv) 2006-11-27

Family

ID=23287695

Family Applications (2)

Application Number Title Priority Date Filing Date
SE0400961A SE528775C2 (sv) 2001-10-15 2004-04-14 Behandling och diagnos av insulinresistenta tillstånd
SE0602516A SE0602516L (sv) 2001-10-15 2006-11-27 Behandling och diagnos av insulinresistenta tillstånd

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE0400961A SE528775C2 (sv) 2001-10-15 2004-04-14 Behandling och diagnos av insulinresistenta tillstånd

Country Status (17)

Country Link
US (3) US20030100504A1 (sv)
JP (1) JP2005506342A (sv)
CN (1) CN1571675A (sv)
AT (1) AT500646A1 (sv)
CA (1) CA2461818A1 (sv)
CZ (1) CZ2004564A3 (sv)
DE (1) DE10297331T5 (sv)
DK (1) DK200400777A (sv)
ES (1) ES2304072B1 (sv)
FI (1) FI20040531A (sv)
GB (1) GB2395903B (sv)
HK (1) HK1063280A1 (sv)
IL (1) IL161198A0 (sv)
LU (1) LU91070B1 (sv)
MX (1) MXPA04003536A (sv)
SE (2) SE528775C2 (sv)
WO (1) WO2003032810A2 (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039578A2 (en) * 2003-10-29 2005-05-06 Macrozyme B.V. Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2006010534A1 (en) * 2004-07-28 2006-02-02 F.Hoffmann-La Roche Ag Dickkopf homolog 3 as target/marker of beta cell failure
JP2008522607A (ja) * 2004-12-09 2008-07-03 ニューロ セラピューティクス エービー Ｄｉｃｋｋｏｐｆｓおよび神経発生に関係した物質および方法
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
CN1963511B (zh) * 2005-11-11 2014-09-24 上海市肿瘤研究所 Dkk-1蛋白在癌症诊断中的应用
JP2011519911A (ja) 2008-05-05 2011-07-14 ノヴィミュンヌ エスア 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
MA33248B1 (fr) * 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline
JP7064452B2 (ja) * 2016-06-30 2022-05-10 ノボ・ノルデイスク・エー／エス インスリン計画アドヒアランスデータの分析のためのシステムおよび方法
CN115124424B (zh) * 2022-06-01 2024-04-05 重庆市食品药品检验检测研究院 非诺贝特半抗原及其制备方法、非诺贝特抗原、抗体及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus

Also Published As

Publication number Publication date
WO2003032810A3 (en) 2004-06-17
CA2461818A1 (en) 2003-04-24
ES2304072A1 (es) 2008-09-01
MXPA04003536A (es) 2004-07-23
GB2395903B (en) 2005-08-31
US20030100504A1 (en) 2003-05-29
SE528775C2 (sv) 2007-02-13
IL161198A0 (en) 2004-08-31
HK1063280A1 (en) 2004-12-24
CZ2004564A3 (cs) 2005-03-16
DK200400777A (da) 2004-05-14
WO2003032810A2 (en) 2003-04-24
GB0407486D0 (en) 2004-05-05
FI20040531A (sv) 2004-04-14
US20050170440A1 (en) 2005-08-04
CN1571675A (zh) 2005-01-26
SE0400961L (sv) 2004-04-14
ES2304072B1 (es) 2009-07-07
JP2005506342A (ja) 2005-03-03
SE0400961D0 (sv) 2004-04-14
AT500646A1 (de) 2006-02-15
US20060293239A1 (en) 2006-12-28
GB2395903A (en) 2004-06-09
DE10297331T5 (de) 2004-11-18
LU91070B1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
SE0602516L (sv) Behandling och diagnos av insulinresistenta tillstånd
EA200300025A1 (ru) Способ лечения патологического синдрома и лекарственное средство
DE60237823D1 (de) Medizinisches behandlungsinstrument
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
FIU20060389U0 (sv) Behandling av bensjukdomar
NO20035157D0 (no) Lungeadministrering av kjemisk modifisert insulin
NO20035522D0 (no) Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom
NO20033594L (no) Fenetanolamin-derivater for behandling av luftveissykdommer
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20014950D0 (no) Nye behandlingsmetoder
FI20011403A (sv) Förfarande och sammansättningar för behandling av magsjukdomar
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60120291D1 (de) Endoskop und Endoskopkapsel
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
NO20041968L (no) Anvendelse av cystationin
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
DE60220220D1 (de) Blutbehandlungssystem
ATE282604T1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten
NO20035605D0 (no) Pediatrisk formulering av gatifloxacin
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
NO20032156D0 (no) Behandling av angstforstyrrelser
ATE352302T1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
PT1381620E (pt) Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes

Legal Events

Date Code Title Description
NAV Patent application has lapsed